Tech Center 1600 • Art Units: 1693
This examiner grants 36% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18554922 | NOVEL USE | Non-Final OA | DSM IP ASSETS B.V. |
| 17767996 | CELLULOSE COMPOSITION AND TABLET | Final Rejection | ASAHI KASEI KABUSHIKI KAISHA |
| 17056800 | PREBIOTIC COMPOSITIONS AND METHODS FOR MAINTAINING A HEALTHY SKIN MICROBIOTA | Non-Final OA | KIMBERLY-CLARK WORLDWIDE, INC. |
| 17799320 | USE OF COMPOUNDS THAT ARE ABLE TO CROSS-LINK THE EXTRACELLULAR MATRIX FOR PREVENTING OR INHIBITING THE MIGRATION OF CANCER CELLS | Non-Final OA | CAMBRIDGE ENTERPRISE LIMITED |
| 17768922 | METHODS OF TREATING CANCER WITH A STING AGONIST | Final Rejection | The Board of Regents of the University of Texas System |
| 17627472 | ECOBIOLOGICAL TREATMENT OF SIDE EFFECTS OF RADIOTHERAPY | Non-Final OA | BIONUCLEI |
| 17705762 | DEPOLYMERIZATION AND VALORIZATION OF A BIOPOLYMER | Non-Final OA | NEW YORK UNIVERSITY |
| 17824446 | INTERMEDIATE METABOLISM PRODUCTS TO POTENTIATE AMINOGLYCOSIDE ANTIBIOTICS IN BACTERIAL INFECTIONS | Final Rejection | THE GENERAL HOSPITAL CORPORATION |
| 18088628 | COMPOUND, SOLID CARRIER INCLUDING THE SAME AND METHOD FOR PREPARING NUCLEIC ACID | Final Rejection | Industrial Technology Research Institute |
| 17906560 | METHODS AND COMPOSITIONS FOR TREATMENT OF CORONAVIRUS INFECTION | Non-Final OA | Battelle Memorial Institute |
| 17996452 | CYCLODEXTRIN BASED ANTI-MICROBIAL THERAPY | Final Rejection | University of Southern California |
| 18176864 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | Gilead Sciences, Inc. |
| 18554318 | A METHYLCELLULOSE WITH HIGH POWDER DISSOLUTION TEMPERATURE | Non-Final OA | Nutrition & Biosciences USA 1, LLC |
| 18249245 | IMPROVED SOPHOROLIPID DERIVATIVES WITH THERAPEUTIC AGENT CARGOS AND THEIR USE | Non-Final OA | LOCUS SOLUTIONS IPCO, LLC |
| 18251510 | MONTBRETIN A FUNCTIONAL FOOD | Non-Final OA | THE UNIVERSITY OF BRITISH COLUMBIA |
| 18061323 | HEPARANASE INHIBITORS FOR TREATMENT OF DIABETES | Final Rejection | Wayne State University |
| 18264879 | METHODS FOR PREVENTING CANCER RELAPSE | Non-Final OA | Department of Veterans Affairs |
| 18564953 | NEW THERAPEUTIC USE OF TYPE 2 IODOTHYRONINE DEIODINASE (D2) INHIBITORS | Non-Final OA | Dompé Farmaceutici S.p.A. |
| 18007407 | NOVEL THERAPEUTIC USES OF COMPOUNDS FOR ENHANCING MITOCHONDRIAL FUNCTION AND TREATING MITOCHONDRIAL DISEASES | Final Rejection | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 18553144 | PYRROLOPYRIMIDINE NUCLEOSIDES FOR TREATING OR PREVENTING A SARS-COV-2 INFECTION | Non-Final OA | Chimerix, Inc. |
| 17636536 | NEW USE OF CYCLIC DINUCLEOTIDES | Final Rejection | Helmholtz-Zentrum für Infektionsforschung GmbH |
| 17927941 | ANTIFUNGAL PRODRUGS | Final Rejection | NANTES UNIVERSITÉ |
| 18484111 | METHODS FOR THE TREATMENT OF PROTEINOPATHIES | Non-Final OA | RENATUS INC. |
| 18554442 | A COMPOSITION FOR IMPROVING GUT MICROBIOTA, BEHAVIOURAL PATTERN, ALPHA-SYNUCLEIN LEVELS, SLEEP PATTERN AND/OR SERUM MELATONIN | Non-Final OA | Sophy Inc. |
| 18549010 | AGENT FOR ENHANCING HAIR-SETTING ABILITY | Non-Final OA | Hayashibara Co., Ltd. |
| 17758495 | Estrogen Metabolite Levels And Cancer Driver Gene Mutations In Lung Cancer Risk Stratification And Treatment | Non-Final OA | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center |
| 18283478 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | Non-Final OA | HK INNO.N CORPORATION |
| 17778297 | METHOD FOR PRODUCING CELLULOSE CARBAMATE | Non-Final OA | ANDRITZ OY |
| 18549452 | STABILIZED LIQUID COMPOSITIONS COMPRISING A LEVODOPA-TYROSINE CONJUGATE AND USES THEREOF | Non-Final OA | NeuroDerm, Ltd. |
| 18460815 | METHOD OF MANUFACTURING AUTO-CROSSLINKED HYALURONIC ACID GEL AND PRODUCTS THEREOF | Non-Final OA | SCIVISION BIOTECH INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy